Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02507284 · ClinicalTrials.gov registry record · Phase 2
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
A Phase 2 study, sponsored by Azevan Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT02507284: Completed Phase 2 study, sponsored by Azevan Pharmaceuticals.
NCT02507284 is a Phase 2 study that has completed, run by Azevan Pharmaceuticals. The registered enrollment target is 106 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02507284, a Phase 2 study, has completed, sponsored by Azevan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease. Two-thirds of all participants will receive SRX246, while the other third will receive a placebo.
Interventions
- DRUG Placebo
- DRUG SRX246
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2016-05-10 |
| Est. Completion | 2018-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02507284
The ClinicalTrials.gov registry entry for NCT02507284 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Azevan Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02507284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02507284 about?
NCT02507284 is a clinical study titled "Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease". This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease. Two-thirds of all participants will receive SRX246, while the other third will receive a placebo.
What is the current status of trial NCT02507284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2016-05-10. Estimated completion is 2018-12-21.
What interventions are being tested in trial NCT02507284?
The interventions under investigation include: Placebo (DRUG), SRX246 (DRUG).
Who is sponsoring clinical trial NCT02507284?
This trial is sponsored by Azevan Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.